PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary OpGen Announces Date of First Quarter 2018 Financial Results Conference Call
GAITHERSBURG, Md. , May 01, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announced today that the Company will report financial results for the three months ended March 31, 2018 after close of the U.S. financial markets on Tuesday, May 8, 2018 . OpGen’s management team will host a live
View HTML
Toggle Summary OpGen Highlights Acuitas® Analytical Validation Data for Rapidly Predicting Antibiotic Resistance Using Drug Resistance Gene Profiles at ECCMID
DNA Sequencing prediction results and evaluation of Acuitas Resistome Test for infection control presented GAITHERSBURG, Md. , April 24, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that it has presented analytical validation results for the Acuitas ® AMR Gene Panel u5.47
View HTML
Toggle Summary OpGen Completes Rapid Testing Clinical Trial in Colombia and Expands International Operations
GAITHERSBURG, Md. , April 19, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) OpGen announced today that it successfully completed a prospective clinical trial evaluating the impact of using rapid diagnostic testing for identification and treatment of bacteremia and fungemia in hospital
View HTML
Toggle Summary OpGen Reports Fourth Quarter and Full Year 2017 Financial Results and Provides a Business Update
Acuitas® AMR Gene Panel u5.47 introduced for Research Use Only Fourth quarter revenue consistent with previous year; net loss decreases 38% year over year Conference call begins at 4:30 p.m. Eastern time today GAITHERSBURG, Md. , March 15, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc.
View HTML
Toggle Summary OpGen Announces Collaborator in Verification Study for Acuitas® Test
Study to evaluate potential utility in management of complicated urinary tract infections GAITHERSBURG, Md. , March 13, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announced today that it is collaborating with Beth Israel Deaconess Medical Center (BIDMC) in Boston on a verification study for
View HTML
Toggle Summary OpGen Announces Date of Fourth Quarter and Fiscal Year 2017 Financial Results Conference Call
GAITHERSBURG, Md. , March 05, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announced today that the Company will report its fourth quarter and fiscal year 2017 financial results after close of market on Thursday, March 15, 2018 . OpGen’s management team will host a live conference call and
View HTML
Toggle Summary OpGen to Present at the Cowen and Company 38th Annual Health Care Conference
GAITHERSBURG, Md. , March 01, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announced today that Evan Jones , Chairman and Chief Executive Officer of the Company, will present a corporate overview at the Cowen and Company 38th Annual Health Care Conference on Tuesday, March 13, 2018 at 8:40
View HTML
Toggle Summary OpGen Strengthens Supplier Relationship to Use Industry-Leading Real-Time PCR Technology for New Acuitas® Tests
Test rapidly detects 47 antimicrobial resistance markers directly from urine and bacterial isolates GAITHERSBURG, Md. , Feb. 13, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announced today that it has entered into a global supply agreement to use Thermo Fisher Scientific’s real-time PCR
View HTML
Toggle Summary OpGen Announces Closing of $12 Million Public Offering
GAITHERSBURG, Md. , Feb. 07, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announces the closing of its previously announced public offering of 2,841,152   units at $3.25 per unit and 851,155 pre-funded units at $3.24 per pre-funded unit, raising gross proceeds of approximately $12 million .
View HTML
Toggle Summary OpGen Regains Compliance With Nasdaq Listing Requirements
GAITHERSBURG, Md. , Feb. 05, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announces that it has received notification from Nasdaq that the minimum bid price deficiency of the Company’s stock has been cured, and it will continue to be listed and traded on The Nasdaq Stock Market .  In
View HTML